EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Detection of circulating tumor DNA in colorectal cancer patients using a methylation‐specific droplet digital PCR multiplex

Luisa Matos do Canto iD, Louise Raunkilde, Jan Lindebjerg, Mads Malik Aagaard, Christina Therkildsen, Jakob Kleif, Lars Henrik Jensen, Torben Frøstrup Hansen, Rikke Fredslund Andersen iD

Molecular Oncology · 2026

DOI: 10.1002/1878-0261.70161 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2026. Verfasst von Luisa Matos do Canto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Immunology, Vejle Hospital, University Hospital of Southern Denmark, Denmark. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Circulating Tumor DNA, DNA Methylation, Multiplex Polymerase Chain Reaction. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Elna og Jørgen Fagerholt's Cancer research fund, Købmand Sven og Ina Hansen's Fund, Købmand Inger Bonnén's Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the use of conventional biomarkers and imaging methods for treatment monitoring of colorectal cancer (CRC) patients, limitations remain in detecting minimal residual disease and early relapse. Circulating tumor DNA (ctDNA) offers a promising noninvasive and cost‐effective alternative for monitoring disease progression and relapse, potentially improving patient outcomes. In this study, we developed a methylation‐specific droplet digital PCR (MS‐ddPCR) multiplex assay designed to detect ctDNA through a combination of tumor‐specific and tissue‐conserved methylation markers. Our objective was to evaluate the performance of this assay in patients with CRC and assess ctDNA dynamics as a prognostic tool in those with metastatic CRC (mCRC). The assay demonstrated high specificity (96.7%) and sensitivity in detecting ctDNA in both patients with localized tumors (64.4%) and mCRC (89.2%). Notably, ctDNA dynamics from baseline to after the first treatment cycle were significantly associated with progression‐free survival (PFS) and overall survival (OS) in mCRC. Classifying patients based on ctDNA‐RECIST (Response Evaluation Criteria in Solid Tumors) and the percent reduction in ctDNA fraction revealed pronounced differences in PFS and OS. Median PFS and OS were 11.4 and 35.3 months for good responders compared with 7.6 (HR = 1.71, 95% CI 0.9–3.25) and 18.4 (HR = 2.15, 95% CI 1.16–3.99) for poor responders, while patients with progressive disease had a median PFS and OS of 5.1 (HR = 4.36, 95% CI 1.91–9.92) and 6.85 (HR = 4.73, 95% CI 2.09–10.7) months. Our multiplex MS‐ddPCR assay provides a sensitive, cost‐effective approach for detecting and quantifying ctDNA in CRC patients, especially in metastatic disease. The ability to monitor ctDNA dynamics holds potential for early treatment response assessment, prognosis, and guiding personalized therapeutic strategies, making it a valuable tool for clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsCirculating Tumor DNADNA MethylationMultiplex Polymerase Chain ReactionHumansMaleFemaleMiddle AgedAgedBiomarkers, TumorPrognosisAdultAged, 80 and over

Stichwörter der Autor:innen

Colorectal Cancercirculating tumor DNAddPCRmethylation

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Biochemistry and Immunology, Vejle Hospital, University Hospital of Southern Denmark, Denmark.
  • Danish Colorectal Cancer Center South, Vejle Hospital, University Hospital of Southern Denmark, Denmark.
  • Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Denmark.
  • Department of Clinical Pathology, Vejle Hospital, University Hospital of Southern Denmark, Denmark.
  • Department of Clinical Genetics, Vejle Hospital, University Hospital of Southern Denmark, Denmark.
  • Gastro Unit, Copenhagen University Hospital, Amager - Hvidovre Hospital, Denmark.

ORCID-Profile: Luisa Matos do Canto, Rikke Fredslund Andersen

Förderung

  • Elna og Jørgen Fagerholt's Cancer research fund
  • Købmand Sven og Ina Hansen's Fund
  • Købmand Inger Bonnén's Fund
  • Vissing Fonden
  • Familien Hede Nielsen's Fund
  • Else og Mogens Wedell-Wedellsborg
  • Hans & Nora Buchard's Fund
  • Elisa F. Hansens Mindelegat

Zitieren

APA

do Canto, L. M., Raunkilde, L., Lindebjerg, J., Aagaard, M. M., Therkildsen, C., Kleif, J., Jensen, L. H., Hansen, T. F., & Andersen, R. F. (2026). Detection of circulating tumor DNA in colorectal cancer patients using a methylation‐specific droplet digital PCR multiplex. Molecular Oncology. https://doi.org/10.1002/1878-0261.70161

Vancouver

do Canto LM, Raunkilde L, Lindebjerg J, Aagaard MM, Therkildsen C, Kleif J, et al. Detection of circulating tumor DNA in colorectal cancer patients using a methylation‐specific droplet digital PCR multiplex. Molecular Oncology. 2026. doi:10.1002/1878-0261.70161

BibTeX
@article{doCanto2026,
  author = {do Canto, Luisa Matos and Raunkilde, Louise and Lindebjerg, Jan and Aagaard, Mads Malik and Therkildsen, Christina and Kleif, Jakob and Jensen, Lars Henrik and Hansen, Torben Frøstrup and Andersen, Rikke Fredslund},
  title = {Detection of circulating tumor DNA in colorectal cancer patients using a methylation‐specific droplet digital PCR multiplex},
  journal = {Molecular Oncology},
  year = {2026},
  doi = {10.1002/1878-0261.70161}
}
Kostenlos starten →